GAVI Alliance gets reduced price offers from Pfizer and GSK

30 July 2013

The price that the GAVI Alliance, a public/private partnership, pays for lifesaving pneumococcal vaccines for children in the world’s poorest countries is set to be reduced under new agreements between GAVI, UNICEF, The World Bank, and pharma giants GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE).

Under previous agreements both manufacturers offered pneumococcal vaccine at $ 3.50 per dose. From now, Pfizer will provide the vaccine at $3.40 per dose with a further reduction to $3.30 per dose from 2014 onwards. The new prices will apply to all doses to be purchased from Pfizer under current contracts, including those awarded under two previous agreements. In addition, GSK will lower the price GAVI pays for its pneumococcal vaccine to $3.40 per dose for this new contract covering the period 2014-2024.

These price reductions by Pfizer and GSK are the third to be announced by GAVI this year. In April, a manufacturer agreed to provide pentavalent vaccine for $1.19 per dose. In May, a low price of $4.50 per dose was secured for human papillomavirus (HPV) vaccine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK